JP6095367B2 - 癌治療のための診断方法および組成物 - Google Patents

癌治療のための診断方法および組成物 Download PDF

Info

Publication number
JP6095367B2
JP6095367B2 JP2012520702A JP2012520702A JP6095367B2 JP 6095367 B2 JP6095367 B2 JP 6095367B2 JP 2012520702 A JP2012520702 A JP 2012520702A JP 2012520702 A JP2012520702 A JP 2012520702A JP 6095367 B2 JP6095367 B2 JP 6095367B2
Authority
JP
Japan
Prior art keywords
patient
vegf
expression level
antagonist
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012520702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532628A5 (OSRAM
JP2012532628A (ja
Inventor
マイク シュミット，
マイク シュミット，
ローラ サンダース，
ローラ サンダース，
ラジーブ ラジャ，
ラジーブ ラジャ，
ラジェシュ， ディー． パテル，
ラジェシュ， ディー． パテル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2012532628A publication Critical patent/JP2012532628A/ja
Publication of JP2012532628A5 publication Critical patent/JP2012532628A5/ja
Application granted granted Critical
Publication of JP6095367B2 publication Critical patent/JP6095367B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2012520702A 2009-07-13 2010-07-12 癌治療のための診断方法および組成物 Expired - Fee Related JP6095367B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22512009P 2009-07-13 2009-07-13
US61/225,120 2009-07-13
US35173310P 2010-06-04 2010-06-04
US61/351,733 2010-06-04
PCT/US2010/041706 WO2011008696A2 (en) 2009-07-13 2010-07-12 Diagnostic methods and compositions for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016255038A Division JP2017099389A (ja) 2009-07-13 2016-12-28 癌治療のための診断方法および組成物

Publications (3)

Publication Number Publication Date
JP2012532628A JP2012532628A (ja) 2012-12-20
JP2012532628A5 JP2012532628A5 (OSRAM) 2013-08-22
JP6095367B2 true JP6095367B2 (ja) 2017-03-15

Family

ID=43227992

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012520702A Expired - Fee Related JP6095367B2 (ja) 2009-07-13 2010-07-12 癌治療のための診断方法および組成物
JP2016255038A Pending JP2017099389A (ja) 2009-07-13 2016-12-28 癌治療のための診断方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016255038A Pending JP2017099389A (ja) 2009-07-13 2016-12-28 癌治療のための診断方法および組成物

Country Status (13)

Country Link
US (2) US20110076271A1 (OSRAM)
EP (1) EP2454380A2 (OSRAM)
JP (2) JP6095367B2 (OSRAM)
KR (1) KR20120106935A (OSRAM)
CN (2) CN102482715A (OSRAM)
AU (1) AU2010273585B2 (OSRAM)
BR (1) BR112012000735A2 (OSRAM)
CA (1) CA2766403A1 (OSRAM)
HK (1) HK1226108A1 (OSRAM)
IL (1) IL216926A0 (OSRAM)
MX (1) MX2012000620A (OSRAM)
SG (2) SG10201510152RA (OSRAM)
WO (1) WO2011008696A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153224A2 (en) * 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
US9255927B2 (en) 2011-05-05 2016-02-09 Duke University Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
US20140348818A1 (en) * 2011-12-29 2014-11-27 Baylor Research Institute Biomarkers of kawasaki disease
MX356802B (es) 2012-01-13 2018-06-13 Genentech Inc Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf.
SG11201406184XA (en) * 2012-03-30 2014-10-30 Genentech Inc Diagnostic methods and compositions for treatment of cancer
WO2014001232A1 (en) * 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
EP2903692B1 (en) 2012-10-08 2019-12-25 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
WO2015013432A1 (en) * 2013-07-23 2015-01-29 Genentech, Inc. Model of colorectal cancer
CN103911451A (zh) * 2014-04-11 2014-07-09 蒋晓东 筛选抗血管生成靶向药物治疗肺癌目标人群的方法
RS58957B1 (sr) * 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
AU2015355731B2 (en) * 2014-12-03 2018-07-26 Aimed Bio Inc. Antibody binding to neuropilin 1 and use thereof
US10801068B2 (en) 2015-10-16 2020-10-13 The Trustees Of Columbia University In The City Of New York JAG1 expression predicts therapeutic response in NASH
US11154598B2 (en) * 2016-03-29 2021-10-26 Université de Paris Compositions comprising secreted extracellular vesicles of cells expressing NFATC4 useful for the treatment of cancer
WO2017181079A2 (en) * 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
WO2017201166A1 (en) 2016-05-17 2017-11-23 Duke University Methods of predicting responsiveness of a cancer to a vegf targeting agent and methods of prognosing and treating cancer
CA3026238C (en) * 2016-06-03 2023-07-25 Samsung Life Public Welfare Foundation Anti-nrp1 antibody screening method
CN106282376A (zh) * 2016-09-27 2017-01-04 上海交通大学医学院附属第九人民医院 一种用于检测bmp9基因表达的反义rna探针
WO2018127599A1 (en) * 2017-01-09 2018-07-12 Secarna Pharmaceuticals Gmbh & Co Kg Oligonucleotides inhibiting the expression of nrp1
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN109828111A (zh) * 2017-11-23 2019-05-31 复旦大学附属肿瘤医院 MFAP5在制备筛选α干扰素干预肝癌敏感人群标志物的制剂中的用途
CN109828114A (zh) * 2017-11-23 2019-05-31 复旦大学附属肿瘤医院 MFAP5蛋白作为筛选α干扰素治疗肝癌敏感人群的试剂盒中的方法及应用
CN113260863A (zh) * 2018-08-17 2021-08-13 豪夫迈·罗氏有限公司 用于心房纤颤的评价中的循环bmp10 (骨形态发生蛋白10)
CN110893238A (zh) * 2018-09-13 2020-03-20 常州大学 抑制血管内皮生长因子活性和表达量的物质在制备抑制淋巴结转移的产品中的应用
CA3115102A1 (en) * 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
CN112213495B (zh) * 2020-09-18 2022-10-28 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广州中医药大学骨伤科研究所) 一种辅助诊断或诊断股骨头坏死的标志物

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU710696C (en) 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998002437A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
PT1695985E (pt) 1997-04-07 2011-06-06 Genentech Inc Métodos para formar anticorpos humanizados por mutagénese aleatória
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP0984930B1 (en) 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
JP2001522853A (ja) 1997-11-11 2001-11-20 ファイザー・プロダクツ・インク 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2020408T3 (da) 1998-05-29 2013-09-30 Sugen Inc Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US20020081597A1 (en) 2000-03-31 2002-06-27 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
US6998234B2 (en) * 2000-11-03 2006-02-14 Oncotech, Inc. Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1638941E (pt) 2003-05-22 2010-08-24 Abbott Lab Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
KR101227817B1 (ko) * 2004-04-14 2013-01-29 제넨테크, 인크. 혈관 발달을 조절하기 위한 ｅｇｆｌ７ 길항제를 포함하는조성물 및 방법
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
JP2007070633A (ja) 2005-09-06 2007-03-22 Lg Electronics Inc 印刷用インキと蛍光体スラリー組成物、これを用いる印刷機及びプラズマディスプレイパネル並びにその製造方法
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
ITRM20060337A1 (it) * 2006-06-27 2007-12-28 Biosoot Srl Gene tem8 (tumor endotelial marker 8) e sue forme di espressione ed usi diagnostici e terapeutici
WO2008128233A1 (en) * 2007-04-15 2008-10-23 University Of Chicago Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr)
EP2222874A2 (en) * 2007-11-09 2010-09-01 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment

Also Published As

Publication number Publication date
BR112012000735A2 (pt) 2016-11-16
US20140099326A1 (en) 2014-04-10
EP2454380A2 (en) 2012-05-23
CN106148547A (zh) 2016-11-23
US20140302056A2 (en) 2014-10-09
MX2012000620A (es) 2012-01-27
CN102482715A (zh) 2012-05-30
JP2012532628A (ja) 2012-12-20
SG10201510152RA (en) 2016-01-28
HK1226108A1 (zh) 2017-09-22
SG177640A1 (en) 2012-02-28
US20110076271A1 (en) 2011-03-31
CA2766403A1 (en) 2011-01-20
AU2010273585A1 (en) 2012-01-19
AU2010273585B2 (en) 2015-04-23
WO2011008696A3 (en) 2011-04-14
JP2017099389A (ja) 2017-06-08
IL216926A0 (en) 2012-02-29
KR20120106935A (ko) 2012-09-27
WO2011008696A2 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
JP6095367B2 (ja) 癌治療のための診断方法および組成物
JP6529261B2 (ja) Ｖｅｇｆアンタゴニストで治療するための患者を同定するための生物学的マーカー
JP5416221B2 (ja) 癌患者における診断用途のための方法および組成物
JP6335875B2 (ja) 癌の治療のための診断法及び組成物
US20100029491A1 (en) Methods and compositions for diagnostic use for tumor treatment
JP5606537B2 (ja) 癌患者における診断使用のための方法及び組成物
WO2011153224A2 (en) Diagnostic methods and compositions for treatment of cancer
HK1167437A (en) Diagnostic methods and compositions for treatment of cancer
HK1170542B (en) Methods and compositions for diagnostics use in cancer patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170214

R150 Certificate of patent or registration of utility model

Ref document number: 6095367

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees